Are Rx-To-OTC Switches Worth The Trouble? Yes They Are, IQVIA Data Shows
Executive Summary
The holy grail of consumer health innovation, Rx-to-OTC switches, are costly and hard to pull off. So, are they worth the effort? An analysis by IQVIA of desloratadine, which was switched in Germany 2020 by Novartis subsidiary, Hexal, shows that they are, with sales of OTC desloratadine products growing 112% between 2019 and 2020.
You may also be interested in...
Top 10 UK OTC Marketing Stories 2021: Switches And Digital Prove Popular
Despite the restrictions on daily life due to the pandemic, 2021 was still a great year for consumer health product marketing, with brands and their agencies devising innovative ways to reach UK consumers. Here we look at HBW Insight's top-10 most read UK marketing stories of 2021, revealing those launches, campaigns and trends which grabbed the attention of readers last year.
UK Weighing Rx-to-OTC Switch Of Menopause Treatment
Novo Nordisk is seeking to switch from Rx-to-OTC status Gina (estradiol hemihydrate), which, if approved, would be the first form of local hormone replacement therapy available without a prescription in the UK.
No OTC Sildenafil In Germany After Committee Rejects All Rx-To-OTC Switches
The German Expert Committee for Prescription has rejected the Rx-to-OTC reclassifications of sildenafil (50mg) for oral use and xylometazoline and ipratropium bromide for intranasal use.